These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28266163)

  • 1. Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.
    Kondo S; Hosoi H; Itahashi K; Hashimoto J
    Cancer Sci; 2017 May; 108(5):995-999. PubMed ID: 28266163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
    Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
    BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
    Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
    Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status and problems in clinical trial for new anticancer drug in Japan].
    Fukuoka M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):141-5. PubMed ID: 8611040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems with registration-directed clinical trials for lung cancer in Japan.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Saijo N; Tamura T
    Tohoku J Exp Med; 2007 Sep; 213(1):17-23. PubMed ID: 17785949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccine THERATOPE- Biomira.
    Adis International Ltd
    Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
    Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
    Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
    Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study.
    Sasaki K; Mizusawa J; Bando H; Nakamura K; Kataoka T; Katayama H; Fukuda H; Hara H
    Trials; 2024 Oct; 25(1):665. PubMed ID: 39375801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to publication of oncology trials and why some trials are never published.
    Chapman PB; Liu NJ; Zhou Q; Iasonos A; Hanley S; Bosl GJ; Spriggs DR
    PLoS One; 2017; 12(9):e0184025. PubMed ID: 28934243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine.
    Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marimastat: BB 2516, TA 2516.
    Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.